RNA-seq profiling of the tumor immune microenvironment in murine prostate cancer models following therapy with an engineered Salmonella typhimurium strain (SLlux/ClyA)

This project contains RNA sequencing data generated to investigate the transcriptomic mechanisms underlying the anti-tumor efficacy of SLlux/ClyA, an attenuated and bioluminescent Salmonella typhimurium strain engineered to express the cytolysin A (ClyA) protein, in prostate cancer models.The dataset comprises transcriptome profiles of RM1 prostate tumors from immunocompetent (C57BL/6) murine models treated with SLlux/ClyA versus untreated controls. RNA-seq was performed on tumor tissues to analyze gene expression changes induced by bacterial therapy. The data reveals significant alterations in the tumor immune microenvironment, including:Innate immune activation: Enrichment of pathways related to neutrophil migration and inflammatory responses.Cytokine signaling: Upregulation of pro-inflammatory genes (e.g., IL-1b, TNF-a, IFN-g).Altered cellular composition: Recruitment of tumor-associated neutrophils (TANs), macrophages (TAMs), and dendritic cells (DCs).This dataset provides a comprehensive resource for understanding how engineered bacteria reprogram the prostate tumor microenvironment, offering insights for combination strategies with immunotherapy.